Fenofibrate for Transplantation, Liver

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Mayo Clinic Arizona, Phoenix, AZ
Transplantation, Liver+1 More
Fenofibrate - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to evaluate the safety and effectiveness of a once-daily medication, fenofibrate (Lofibra), to prevent ischemic cholangiography (IC) in persons who were transplanted with livers donated after circulatory death (DCD).

Eligible Conditions

  • Transplantation, Liver

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 12 weeks

12 weeks
Efficacy of fenofibrate
Serum biomarker association with development of IC
Tolerability of fenofibrate
Week 4
Safety of fenofibrate

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

Recipients of DCD liver transplants
1 of 1
Experimental Treatment

148 Total Participants · 1 Treatment Group

Primary Treatment: Fenofibrate · No Placebo Group · Phase 2

Recipients of DCD liver transplants
Drug
Experimental Group · 1 Intervention: Fenofibrate · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fenofibrate
2018
Completed Phase 4
~6500

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 12 weeks

Trial Background

Channa R Jayasekera,c, MD
Principal Investigator
Mayo Clinic
Closest Location: Mayo Clinic Arizona · Phoenix, AZ
Photo of mayo clinic arizona  1Photo of mayo clinic arizona  2Photo of mayo clinic arizona  3
2005First Recorded Clinical Trial
1 TrialsResearching Transplantation, Liver
146 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a serum alkaline phosphatase level >2.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.